This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Valeant Is Having a Healthy Run

What a phenomenal run its CEO has given to shareholders of the company.

Valeant is a $37 billion, large-cap, multinational pharmaceutical company headquartered in Montreal. It develops and markets prescription brands, branded generics, and over-the-counter consumer products. Currently Valeant has several drugs in their pipeline, including drugs to treat epilepsy and dermatological and ophthalmological issues.


That sounds great. But the real story is in the stock performance.

Data from Best Stocks Now App

Over the last 10 years Valeant has delivered 24% per year to investors, while the market has delivered only 5%. And over the last five years, Valeant was one of the top-performing stocks in the entire market, with 69% returns per year to investors -- more than quadruple the market return of 14%.

For the last 12 months, the stock is up 88%. Again it's more than tripled and even almost quadrupled the returns of the market.

Lest you accuse me of being a momentum investor, half of my purchase formula is valuation. I don't like buying stocks that are at or near new highs. But I am a big believer in performance. I like to buy the best-performing stocks in the market. Sorry, Pfizer and Lilly. Hello, Valeant.


Must Read: [video] Quick Take: Jim Cramer: Buy Shares of Apple on Share Price Weakness

A stock must also meet my valuation criteria, which VRX passes. I currently have a five year target price of $205 on the share.

Data from Best Stocks Now App

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VRX $88.20 1.30%
AAPL $119.24 1.20%
FB $105.21 -0.23%
GOOG $750.20 -0.01%
TSLA $230.82 -0.34%


Chart of I:DJI
DOW 17,797.52 -0.97 -0.01%
S&P 500 2,085.67 -4.44 -0.21%
NASDAQ 5,117.0420 -10.4830 -0.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs